Use of a 2.5% Cross-Linked Polyacrylamide Hydrogel in the Management of Joint Lameness in a Population of Flat Racing Thoroughbreds: A Pilot Study.
Authors: de Clifford Leigh T, Lowe Jason N, McKellar Campbell D, Bolwell Charlotte, David Florent
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Cross-linked polyacrylamide hydrogel for joint lameness in racing Thoroughbreds Osteoarthritis accounts for approximately 60% of lameness cases in equine athletes, making joint disease a significant welfare and economic concern in racing populations. De Clifford Leigh and colleagues conducted a prospective longitudinal study of 49 flat-racing Thoroughbreds at a single training facility to evaluate whether intra-articular injection of 2.5% cross-linked polyacrylamide hydrogel (PAAG) could improve lameness in carpal and metacarpophalangeal joint disease. Lameness grades showed statistically significant improvement at weeks 1, 4, 12, and 24 post-treatment (P < 0.01 to P < 0.001), suggesting a sustained therapeutic response across both immediate and longer-term timeframes. Whilst these findings are encouraging and support PAAG as a potentially safe joint treatment option for managing osteoarthritis in racehorses, the pilot design and lack of blinded controls limit definitive conclusions about efficacy and mechanism of action. Practitioners considering this intervention should recognise its preliminary evidence base and await further controlled trials before integrating it into routine lameness management protocols, though the sustained improvement observed warrants continued investigation.
Read the full abstract on PubMed
Practical Takeaways
- •This pilot study suggests 2.5% cross-linked PAAG may be a viable treatment option for managing carpal and metacarpophalangeal joint lameness in racing Thoroughbreds, with sustained improvement over 24 weeks
- •Results are preliminary and require blinded, controlled studies before clinical recommendations can be made
- •The treatment appears safe, but mechanism of action requires further investigation
Key Findings
- •2.5% cross-linked polyacrylamide hydrogel showed significant improvement in lameness grades at weeks 1, 4, 12, and 24 compared to baseline (P < 0.001 at weeks 4, 12, and 24)
- •Treatment was safe and effective in managing joint lameness in flat-racing Thoroughbreds
- •Osteoarthritis accounts for up to 60% of all lameness in equine athletes